Aligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Significant Drop in Short Interest

Aligos Therapeutics, Inc. (NASDAQ:ALGS) saw a significant drop in short interest in April. As of April 15th, there was short interest totalling 657,200 shares, a drop of 24.4% from the March 31st total of 868,800 shares. Based on an average daily volume of 388,300 shares, the days-to-cover ratio is presently 1.7 days.

Aligos Therapeutics Price Performance

ALGS opened at $0.78 on Friday. The firm has a market capitalization of $59.17 million, a PE ratio of -0.49 and a beta of 2.34. The business’s 50-day moving average is $0.91 and its two-hundred day moving average is $0.76. Aligos Therapeutics has a 1 year low of $0.54 and a 1 year high of $1.38.

Aligos Therapeutics (NASDAQ:ALGS) last released its quarterly earnings results on Tuesday, March 12th. The company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.05. The business had revenue of $2.68 million for the quarter, compared to analysts’ expectations of $3.20 million. Aligos Therapeutics had a negative net margin of 607.03% and a negative return on equity of 116.41%. As a group, sell-side analysts expect that Aligos Therapeutics will post -0.83 EPS for the current year.

Hedge Funds Weigh In On Aligos Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in shares of Aligos Therapeutics by 1.6% during the 3rd quarter. Vanguard Group Inc. now owns 1,010,617 shares of the company’s stock valued at $755,000 after purchasing an additional 15,905 shares during the last quarter. Newtyn Management LLC raised its stake in Aligos Therapeutics by 2.2% in the third quarter. Newtyn Management LLC now owns 920,000 shares of the company’s stock valued at $687,000 after buying an additional 20,000 shares during the last quarter. Opaleye Management Inc. acquired a new stake in Aligos Therapeutics in the fourth quarter worth about $861,000. Altitude Crest Partners Inc. acquired a new stake in Aligos Therapeutics in the fourth quarter worth about $1,889,000. Finally, Armistice Capital LLC purchased a new stake in shares of Aligos Therapeutics during the fourth quarter worth about $4,538,000. 60.43% of the stock is owned by hedge funds and other institutional investors.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).